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Desensitization of angiotensin receptor function. Angiotensin II is an
eight amino acid peptide which plays a major role in the regulation of
cardiovascular homeostasis. The physiologic effects of angiotensin (Ang)
II are mediated by a G-protein coupled receptor, termed AT1, which
activates phospholipase C. A major factor regulating angiotensin II
receptor function is the rapid desensitization following agonist stimula-
tion. However, despite years of investigation, the mechanism by which the
angiotensin receptor is regulated remains unclear. The cloning of the
AT-i receptor and the availability of cell lines which stabily express this
receptor has helped elucidate these mechanisms. In this paper, we review
the data from our laboratory concerning the post-translational regulation
of the angiotensin receptor function.
Angiotensin (Ang) II is the effector molecule of the renin-
angiotensin-aldosterone system. An eight amino acid peptide,
Ang II exerts a wide range of actions in the kidney, heart, vascular
system, adrenal gland and central nervous systems. In the past, it
was thought that the main physiologic consequences of this
peptide was an increase in vascular tone as well as salt and water
retention. However, it is now apparent that this peptide exerts
numerous other actions such as the regulation of gene transcrip-
tion and the regulation of vascular, cardiac, mesangial and adrenal
growth, both physiologic as well as pathologic [reviewed in 1].
Ang II exerts its actions via a family of membrane bound
receptors that are widely distributed. Based on ligand binding
experiments, two major types of specific Ang II binding sites have
been defined and designated AT1 and AT2 [2, 3]. To date, a vast
majority of the physiologic actions of Ang II in the normal, adult
animal appear to be due to the actions of the AT1 class of
receptors. Several investigators have succeeded in the molecular
cloning of the AT1 receptors from numerous species [4—7]. The
combined results indicate that the Ang II receptor belongs to the
super family of seven transmembrane, G-protein coupled recep-
tors. In some species, we and others have demonstrated the
presence of two subtypes of the AT1 receptor which have been
termed AT1a and AT1b [5, 6]. These two subtypes are highly
homologous, in the mouse differing by only 22 amino acids out of
359. No obvious difference in ligand binding characteristics signal
transduction or rapid desensitization could be shown; however,
differences in tissue distribution exist. The ATia was found to be
distributed in a wide range of tissues while the ATib was restricted
to the adrenal gland and kidney.
Over the years multiple lines of investigation from many
laboratories have shown that the regulation of the Ang II receptor
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function is a complex yet physiologically important process. It has
been demonstrated in whole animal, isolated vessels and in
cultured cells that the Ang II receptor undergoes rapid tachyphy-
laxis or desensitization since repeated administration of ligand
fails to elicit a response comparable to the initial response. Prior
to the molecular cloning of the receptor, the mechanism for this
desensitization was unclear. Based on studies with other seven-
transmembrane receptors, we have hypothesized that protein
kinase C, which is activated as part of the angiotensin receptor
signaling cascade, would mediate the agonist-induced desensiti-
zation of this receptor. However, this is a controversial point
[8—11]. With the availability of the cloned eDNA from many
species, the processes involved in the tachyphylaxis of the receptor
can be easily examined.
Characterization of the murine angiotensin receptors
Recent advances in murine embryology have made it possible to
develop strains of mice overexpressing mutant genes or harboring
targeted gene disruptions. Therefore, aiming towards future ex-
periments, we have chosen to investigate the murine angiotensin
receptor. A murine genomic library was screened with a PCR
derived eDNA probe complementary to the mouse AT1 cDNA
[5]. Multiple positive genomic clones were isolated and shown by
restriction mapping to encode two distinct clones which were
termed ATia and AT1b. Sequence analysis demonstrated that
these clones were highly homologous, differing in only 22 out of
359 amino acids (93.9% homology). The amino acid differences
were distributed through out the molecule but were particularly
prevalent in the carboxy terminal intracellular domain. Of partic-
ular interest are differences involving serine residues which may
reflect differences in phosphorylation and subsequent desensiti-
zation [5]. Binding studies were performed on membranes from
COS-7 cells transfected with expression vectors encoding the two
isoforms which confirmed their designation as AT1 receptors. No
significant differences were noted in the binding or competition
profiles for the two isoforms. Using a RT-PCR based assay, the
tissue distribution of the two isoforms was examined. ATia
transcripts were the predominant form in most tissues including
the kidney, heart, liver and brain while the AT1b was the predom-
inant form in the adrenal gland.
Expression plasmids coding for epitope-tagged AT1 receptor
were constructed by inserting the coding region of the mouse
ATia and AT1b receptors [5] into the eukaryotic expression vector
pBC12BI [12]. Cells expressing the receptors were cloned after
selection with G418 (800 mg/mI) and analyzed by binding studies.
Scatchard analysis demonstrates that the expression of the two
receptors was similar, (ATia, Bmax = 235,000 sites/cell, Kd =
1499
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1.9 n; AT1b Bm = 216,000 sites/cell, K. = 1.2 nM). We next
examined the signal transduction cascade initiated by these two
receptor isoforms. Measurements of intracellular calcium concen-
trations were performed by loading cells with 10 JiM Fura-2-AM
for 20 minutes at 37°C. Values of intracellular calcium concen-
tration were calculated according to the method of Grykiewicz,
Poenie and Tsien [131. Measurements of angiotensin Il-induced
1P3 levels were performed by stimulating cells with angiotensin II
and 1P3 levels in the supernatant were assayed using a competitive
binding assay (NEN). Both isoforms elicited transient increases in
1P3 levels and intracellular calcium. Moreover, the magnitude and
kinetics were virtually identical.
Desensitization of receptor function
The availability of stabily transfected 293 cells, expressing the
AT1 receptor subtypes has provided a unique model system to
examine the mechanism of desensitization of these receptors.
Previous studies have shown that the angiotensin receptor exhibits
agonist-induced desensitization [14], which could account for the
commonly observed phenomenon of tachyphylaxis to the actions
of angiotensin II [15]. However, the mechanisms of angiotensin
receptor desensitization have not been clarified. By comparison to
other seven transmembrane receptor systems, we hypothesize that
PKC should be involved in the desensitization of this receptor.
However, this point is controversial. For example, in a study of
neonatal rat cardiac ventricular myocytes, Abdellatif et al. [101
reported that PKC did not play a major role in the agonist-
induced desensitization of the angiotensin receptor, whereas
Pfeilschifter and co-workers [9—111 found that PKC appeared to
be involved in the agonist-induced desensitization of the angio-
tensin receptor in rat mesangial cells. Since these investigators
were using different tissue sources, different doses of Ang II and
different methods to inhibit PKC (depletion of P1CC by chronic
pretreatment with the phorbol ester PMA, versus the use of PKC
inhibitors such as H-7 and sphingosine), these results are not
directly eomparable.
Using stabily transfected cell lines, we have examined agonist-
induced desensitization. Cells were stimulated with Ang II
(10—v M). Various times later, the agonist was removed by rinsing
cells with 100 mat NaCl, 50 mat glycine (pH 3.0) followed by
rinsing with PBS. Cells were then stimulated again with Ang II
(i0— M) for 15 seconds, harvested and the extracts assayed for
1P3. The results demonstrated that within 5 to 10 minutes of the
initial stimulation, Ang II no longer stimulated an increase in 1P3,
demonstrating that complete desensitization had occurred. The
dose response relationship for the desensitization was examined
and the ED50 shown to be 3 X i0 M. The agonist induced
desensitization could be mimicked by the PKC activating phorbol
ester, PMA. Furthermore, we found that PMA-induced desensi-
tization could be blocked by staurosporin (P1CC antagonist) or by
down-regulation of PKC by prolonged pretreatment with high
dose PMA. Thus, our results demonstrate that PKC activation can
result in the desensitization of the AT1 receptors. Similar results
were obtained for the AT1b isoform.
We then examined if PKC mediated the desensitization of the
Ang II receptors induced by agonist. At low doses of Ang II
(10—10 M), inhibition of PKC with staurosporine or down-regula-
tion of PKC with 24 hour treatment with PMA blocked agonist
induced desensitization of the AT1a receptor. However, at high
doses of Ang II (10 M), inhibition or down regulation of PKC
had no effects. These results suggest the involvement of both PKC
dependent and P1CC independent pathways in the desensitization
of AT1 receptor isoforms. Preliminary studies indicate that the
characteristics of desensitization of AT1 a subtype are qualitatively
similar to those for the AT1b subtype.
Agonist-induced loss of surface receptors
We next asked if the desensitization of the AT1 receptors was
due to the internalization or sequestration of the receptors.
Angiotensin stimulation results in a loss of cell surface receptors
as determined by binding to the hydrophilic antagonist 1251-Sarl
Ile8-Ang II. However, the rate of disappearance of the receptors
from the cell surface is considerably slower than the rate of
agonist induced desensitization. These results suggest that loss of
cell surface receptors does not contribute to the rapid agonist
induced desensitization, but may play a role in maintaining the
desensitized state. This loss of cell surface receptors following
agonist stimulation has been observed for other G-protein cou-
pled receptors. While it has been proposed to contribute to
desensitization, the role of receptor induced internalization in
receptor regulation remains unknown.
Discussion
The results of this study demonstrate that the regulation of
angiotensin receptor function is a complex process involving
uncoupling of the receptor from its effector as well as the
sequestration/internalization of the receptor (Fig. 1). Agonist-
induced desensitization occurred rapidly, within minutes of incu-
bation with angiotensin II, and was maximally effective at high
(saturating) concentrations of the agonist. The processes of
desensitization and internalization/sequestration appear to be
different processes. The desensitization is temporally distinct from
internalization/sequestration, which occurs at a significantly
slower rate. Moreover, desensitization could be induced by PKC
activation and (at low doses of angiotensin) PKC appears to be
the mechanism by which desensitization occurs (Fig. 1).
What might be the physiologic relevance of the dual regulatory
pathways of the angiotensin receptor desensitization? Circulating
levels of angiotensin II are in the p range, significantly lower
than the 1C of the receptor and in the range where the PKC-
dependent mechanism may play a role in the desensitization. On
the other hand, we and others have speculated that the local
generation of angiotensin II within tissues may result in signifi-
cantly higher levels of angiotensin II. This is a controversial area,
moreover, the levels of angiotensin that may result from these
local systems are not known. However, it is conceivable that the
local concentration of peptide may be greater than in the systemic
circulation and may reach levels where the PKC-independent
mechanism may play an important role in the regulation of
receptor signaling.
In summary, our results indicate that both of the recently
discovered subtypes of the AT1 receptor cause signal transduction
by the inositol phospholipid/calcium signaling pathway. Desensi-
tization of the two subtypes of the AT1 receptor occurs within
minutes of agonist treatment, and is maximal at concentrations of
the agonist higher than 10 nat. Although P1CC-dependent mech-
anisms were involved in agonist-induced desensitization at low
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Fig. 1. Schematic representation of the desensitization of the Ang II receptor.
The interaction of the receptor and ligand results in the activation of
phospholipase C (PLC) via the coupling of the receptor with G proteins
(stage 1). The receptor becomes uncoupled very rapidly following ligand
addition by PKC dependent and independent mechanisms (perhaps via
phosphoiylation of the receptor (*), stage 2). This is followed by the in-
ternalization of the receptor with the subsequent recycling and/or degra-
dation of the receptor and the degradation of the ligand (stage 3).
concentrations of agonist, the high dose agonist-induced desensi-
tization was mediated by a non-PKC pathway. Also, loss of surface
AT1 receptor binding occurred for the two receptor isoforms by
non-PKC dependent mechanisms. It is interesting to note that we
have not found any differences in the regulation of AT1a and AT1b
receptor subtypes in this study using transfected 293 cells. Our
data have not excluded cell or tissue specific mechanisms of
receptor subtype regulation. The significance of the presence of
two Al'1 receptor subtypes in the mouse is still unclear at this
time.
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